Clinical Trial

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2023-12-26; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2024-04-11
Trial Details
NCT Number NCT06182774
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Canadian Institutes of Health Research (CIHR), Myeloma Canada
Conditions Multiple Myeloma
Enrollment 570 participants
Start Date 2024-04-10
Primary Completion 2032-01-31 (estimated)
Study Completion 2032-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14